Lasmed LTD. Liability CO.

Lasmed LTD. Liability CO., a for-profit limited liability company based in Mountain View, California, develops diagnostic medical devices and biomarker-measurement instruments for federal health research agencies as a prime recipient, competing full-and-open without set-aside designation across a narrow customer base.

The company's federal footprint is concentrated entirely within the Department of Health and Human Services National Institutes of Health ecosystem. The top five funding components account for 91% of recent awards by count: NIH's National Heart Lung and Blood Institute ($36 thousand combined potential value on one award), the NIH Clinical Center ($30 thousand on two awards), and NIH's National Institute of Neurological Disorders and Stroke, National Cancer Institute, and Office of the Chief Operating Officer each anchoring smaller awards. By potential value, the National Heart Lung and Blood Institute leads at $36 thousand, but this concentration signal reflects the sparse funding picture — the combined potential value across all eleven awards totals only $70 thousand, while obligated dollars reach $6.3 million, indicating that actual invoiced work substantially exceeds the award ceiling values recorded in the source.

Lasmed's recent capability work centers on development and validation of biomarker signatures for peripheral neuropathic pain. Two National Institute of Neurological Disorders and Stroke project grants awarded September 1, 2022, support discovery and validation of a novel response biomarker signature using diode-laser-selective stimulation (DLSS) to assess C and AD nociceptors in peripheral sensory neuropathy. One grant carries an ultimate completion date of April 30, 2026; the second extends to April 30, 2028. A single small purchase order from the NIH Clinical Center in September 2022, valued at $15,958.80, represents Lasmed's contract footprint; the bulk of federal engagement flows through research project grants rather than procurement contracts.

Award activity is episodic. The vendor holds eleven awards spanning 2002 to 2022, with no awards in the source data after September 2022. One award reaches completion inside the next twenty-four months. Lasmed operates as a 100% prime recipient across contract and grant awards, with no recorded subcontract or sub-recipient activity.